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ABSTRACT
Objective: To assess whether MS genetic risk polymorphisms (single nucleotide polymorphism
[SNP]) contribute to the enhanced humoral immune response against Epstein-Barr virus (EBV)
infection in patients with MS.
Methods: Serum anti-EBV nuclear antigen 1 (EBNA-1) and early antigen D (EA-D) immunoglobulin
g (IgG) levels were quantitatively determined in 668 genotyped patients with MS and 147 healthy
controls. Anti–varicella-zoster virus (VZV) IgG levels were used as a highly prevalent, non-MS–
associated control herpesvirus. Associations between virus-specific IgG levels and MS risk SNPs
were analyzed.
Results: IgG levels of EBNA-1, but not EA-D and VZV, were increased in patients with MS com-
pared with healthy controls. Increased EBNA-1 IgG levels were significantly associated with risk
alleles of SNP rs2744148 (SOX8), rs11154801 (MYB), rs1843938 (CARD11), and
rs7200786 (CLEC16A/CIITA) in an interaction model and a trend toward significance for
rs3135388 (HLA-DRB1*1501). In addition, risk alleles of rs694739 (PRDX5/BAD) and
rs11581062 (VCAM1) were independently associated and interacted with normal EBNA-1
IgG levels. None of these interactions were associated with EA-D and VZV IgG titers.
Conclusions: Several MS-associated SNPs significantly correlated with differential IgG levels
directed to a latent, but not a lytic EBV protein. The data suggest that the aforementioned
immune-related genes orchestrate the aberrant EBNA-1 IgG levels. Neurol Neuroimmunol
Neuroinflamm 2017;4:e406; doi: 10.1212/NXI.0000000000000406
GLOSSARY
CI5 confidence interval; EA-D5 early antigen D; EBNA-15 Epstein-Barr nuclear antigen 1; EBV5 Epstein-Barr virus; HC5
healthy control; HLA5 human leukocyte antigen; IgG5 immunoglobulin g; IM5 infectious mononucleosis;miR5micro RNA;
NF-kB 5 nuclear factor kappa B; OR 5 odds ratio; SNP 5 single nucleotide polymorphism; VCA 5 viral capsid antigen;
VLA-4 5 very late antigen 4; VZV 5 varicella-zoster virus.
The etiology of MS involves genetic and exposure to environmental factors, including Epstein-
Barr virus (EBV) infection.1–3 Genetic risk factors for MS include specific human leukocyte
antigen (HLA) alleles and currently approximately 100 mainly adaptive immune-related single
nucleotide polymorphisms (SNPs) with modest odds ratios (ORs) compared with the major
HLA-DRB1*1501 association4–6 and EBV exposure.7
Almost all patients with MS are infected with EBV, compared with 90%–95% in healthy
controls (HCs).7,8 A history of EBV-related infectious mononucleosis (IM) and elevated
EBV nuclear antigen 1 immunoglobulin g (IgG) levels increases the risk to develop MS later
in life.9–11 Recently, a meta-analysis showed that antibodies against the latency-associated
Epstein-Barr nuclear antigen 1 (EBNA-1) are consistently increased in patients with MS compared
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with healthy EBV carriers, whereas results for
the lytic viral capsid antigen (VCA) and early
antigen D (EA-D) are more heterogeneous.7
Epidemiologic and genetic studies support
interactions between EBV and HLA-
DRB1*15 on an additive scale.12–14 Whether
the MS risk SNPs are associated with
enhanced IgG levels against EBV is currently
unclear.13,14
We hypothesized that certain MS risk SNPs
are involved in the increased humoral immune
response against EBV. Serum IgG levels
against the EBV antigen EBNA-1 were mea-
sured and associations with MS risk SNPs
were assessed.
METHODS Patients and controls. Consecutive patients
with MS (n 5 668) seen at the MS center ErasMS between
2003 and 2013 were included. A diagnosis of MS was made based
on the 2005 McDonald criteria for MS15 and subclassified as
clinically isolated syndrome, primary progressive, relapsing-
remitting, or secondary progressive MS based on the clinical
course of disease. Unrelated HCs (n 5 147) were persons
accompanying patients with MS to our outpatient clinic. HCs
were age matched to the patients with MS. Exclusion criteria for
HCs to participate in this study were prior neurologic symptoms
suggestive of MS or the use of immunomodulatory drugs for
other autoimmune diseases.
Standard protocol approvals, registrations, and patient
consents. This study was performed according to the guidelines
specified in the Declaration of Helsinki and approved by the
Medical Ethical Committee of the Erasmus MC, and all partici-
pants provided written informed consent.
Determination of IgG levels against viral proteins. Plasma
from blood collection tubes containing EDTA (BD) was used to
measure IgG levels against EBNA-1, EA-D, and varicella-zoster
virus (VZV) as a control. Subsequently in samples negative for
EBNA-1 and EA-D, we measured anti-VCA IgG to ascertain
anti-EBV serostatus. All samples were determined using well-
validated chemiluminescent assays and IgG levels measured on
a Liaison XL (all DiaSorin, Saluggia, Italy) according to the
manufacturers’ guidelines at the National Referral Center for
Virus Diagnostics at the Erasmus MC. All samples were auto-
matically diluted by a factor 20 by the Liaison XL. If antibody
levels were below or above the threshold, these samples were
reanalyzed undiluted or manually prediluted by factor 10 and
subsequently diluted by the Liaison XL, respectively. Using this
protocol, all samples were in the linear range of the assays. Pa-
tients negative for EBNA-1, EA-D, and VCA IgG were omitted
from further study to prevent bias between patients with MS and
HCs due to differences in EBV seroprevalence.
DNA isolation and genotyping. Genomic DNA was isolated
from peripheral blood cell pellets using standard laboratory tech-
niques. Isolated DNA was resuspended in Tris-EDTA (pH 5
7.5) buffer and stored at 220°C. Genotyping was performed
using the Illumina 610K Quad array (Illumina, San Diego,
CA) or Sequenom platform (on both platforms, genotyping was
performed in 1 run according to good laboratory practice follow-
ing the manufacturers’ protocol) for 78 MS-associated risk SNPs
at the Erasmus MC4,5 (table e-1 at Neurology.org/nn). All SNPs
were in the Hardy-Weinberg equilibrium (all p values .0.30).
Statistical analysis. IgG levels for EBNA-1, EA-D, and VZV
were 10 log transformed to normalize titers. T-tests were used to
compare groups, and analysis of variance was used to compare
more than 2 groups (clinical parameters: use of immunomodu-
latory drugs, age, sex, and disease form). For logistic regression,
IgG levels were dichotomized as above or below the 75th per-
centile, and the ORs for MS risk SNPs were determined. In the
first phase of this study, 330 patients with MS were included, and
all MS risk SNPs included in this study (table e-1) were assessed.
All SNPs (in interaction) associated with EBNA-1 IgG with
a p value ,0.10 (i.e., VCAM-1, PRDX5, SOX8, MYB,
CARD11, CLEC16A, and HLA-DRB1*1501), EBNA-1, EA-D,
VZV, and optionally VCA IgG levels were subsequently deter-
mined in a validation cohort of 336 patients with MS and 147
HCs. All associations were confirmed in the validation cohort.
Subsequently, both data sets were pooled for further analysis.
Lastly, interaction models between MS risk SNPs associated with
IgG levels were constructed using forward conditional logistic
regression. Initially, in a univariate model, SNPs associated with
increased EBV IgG were identified. Subsequently, the most sig-
nificant SNP was assessed in an interaction term with all re-
maining SNPs. Significant interactions were subsequently taken
into the next model with an additional SNP in the interaction
term, until no more significant interactions were found. Lastly,
using this interaction term, remaining interactions between the
other SNPs were assessed using the same method. Logistic
regression models were determined both uncorrected and cor-
rected for aforementioned clinical parameters. If the number of
homozygous SNP carriers was smaller than 40 persons, this group
was pooled with heterozygous allele carriers.
Using bootstrapping analysis, 95% confidence intervals (CIs)
were calculated, with 10,000 random samples from the assessed
population with a bias-corrected accelerated method (unless oth-
erwise indicated). All analyses were performed using SPSS version
20 (IBM Corp., Armonk, NY).
p Values ,0.05 were considered statistically significant, and
significance is indicated in the figures as *p , 0.05, **p , 0.01,
and ***p , 0.001. Graphs were constructed using GraphPad
Prism version 5.04 (GraphPad Software Inc., La Jolla, CA).
Table 1 Clinical and demographic characteristics of patients and controls
HC (n 5 147) MS (n 5 668) p Value
Age at sampling (SD) in years 41 (12) 42 (13) 0.46
Age at onset (SD) in years NA 34 (11) NA
No. of female:male 78:60 477:190 5 3 1024
Disease duration in months (IQR) NA 98 (13–152) NA
CSF abnormal, % 82
IgG index raised, % 72
Oligoclonal bands NA NA
Multiple, % 61
1 additional, % 12
Treated patients, % NA 17 NA
Abbreviations: HC 5 healthy control; IgG 5 immunoglobulin g; IQR 5 interquartile range;
NA 5 not applicable.
CSF abnormal defined as either oligoclonal bands specific in CSF or a raised IgG index
.0.67 or both.
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RESULTS Patients and controls. Patients with MS and
HCs were age matched; however, the sex distribution
was significantly different. Demographic characteristics
and clinical information are shown in table 1.
EBV seroprevalence and EBNA-1 IgG levels are increased
in patients with MS compared with controls. More pa-
tients with MS (665 of 668; 99.6%) compared with
HCs (131 of 147; 89.1%) were EBV seropositive
based on EBNA-1, EA-D, and VCA IgG levels (OR
29.0, 95% CI 8.4–100.5; p 5 1 3 1027, figure 1).
This difference in EBV seroprevalence was irrespective
of HLA-DRB1*1501 carriership (HLA-DRB1*1501
adjusted OR 43.6, 95% CI 9.7–196.7; p5 93 1027).
No difference in VZV seropositivity between MS
and HCs was observed (p 5 0.40, figure 1). In
addition, EBNA-1 IgG levels were higher in patients
with MS compared with healthy EBV carriers (HEC)
(p5 93 1027, figure 2A). Differences in EBNA-1 IgG
levels were not related to sex differences (p 5 0.36,
figure 2D), clinical disease course (p5 0.16, figure 2E),
or immunomodulatory drug treatment (p 5 0.62,
figure 2F). By contrast, no differences were observed for
EA-D (p 5 0.55, figure 2B) and VZV IgG levels
between MS and HCs (p 5 0.08, figure 2C).
HLA-DRB1*1501 is associated with enhanced serum
EA-D IgG levels. EBNA-1, EA-D, and VZV IgG levels
were dichotomized as above or below the 75th
percentile of patients with MS. Subsequently, the
OR of HLA-DRB1*1501 carriers for high IgG
levels was determined. Previous associations of
HLA-DRB1*1501 with elevated EBNA-1 IgG titers12
showed a trend for significance (OR 1.43, 95% CI
0.96–2.13; p 5 0.08) using a multivariate logistic
regression model (figure 3A). Moreover, we observed an
association of HLA-DRB1*1501 with EA-D IgG levels
(OR 2.08, 95% 1.19–3.64; p 5 0.01), but not VZV
(data not shown).
PRDX5 and VCAM1 protective alleles are associated with
elevated EBNA-1 IgG levels. Next, we assessed the OR
of 78 MS-associated risk SNPs (table e-1) for high
serum EBNA-1, EA-D, and VZV levels. The non-MS
Figure 1 Flowchart of the study and virus seroprevalence
Immunoglobulin g (IgG) levels against varicella-zoster virus (VZV) and the Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA-
1) and early antigen D (EA-D) peptides were determined. For EBNA-1 and EA-D IgG double-negative patients, viral capsid
antigen (VCA) IgG was assessed to ensure EBV serostatus. IgG levels against VZV was used as a highly prevalent herpes
control virus to assure the specificity of the outcomes. EBNA-1, EA-D, and VCA triple negative patients were excluded from
further study. CI 5 confidence interval; OR 5 odds ratio.
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risk alleles of PRDX5 (OR 0.63, 95% CI 0.42–0.95;
p 5 0.028) and VCAM1 (OR 0.54, 95% CI 0.36–
0.81; p 5 0.003) were correlated with high EBNA-1
IgG levels. Conversely, MS risk alleles of MYB, SOX8,
CARD11, CLEC16A, and HLA-DR showed a trend
toward significance for high EBNA-1 IgG levels
(p, 0.10, figure 3A). No significant differences were
found for the remaining 71 MS risk SNPs. No
association between these MS risk SNPs and EA-D
IgG and VZV IgG was found (all p . 0.52).
Complex interaction between VCAM1-PRDX5 and
SOX8-MYB-CARD11-CLEC16A associated with EBNA-1
IgG. Next, we assessed whether interactions between
MS risk SNPs are associated with the enhanced
anti-EBNA-1 humoral response observed in patients
with MS. All associated SNPs with p , 0.10 and
HLA-DRB1*1501 (figure 3A) were included in
logistic regression models with interaction terms.
Interaction was observed between the non-MS risk
polymorphisms in VCAM1 and PRDX5 (p 5 0.01,
figure 3B) in association with high EBNA-1 IgG
levels. A second interaction term between the risk
alleles of SOX8-MYB-CARD11-CLEC16A was
associated with high EBNA-1 IgG (p 5 0.004). In
a combined model, HLA-DRB1*1501 was not
associated with increased EBNA-1 IgG titers (p 5
0.1, figure 3B). Adjustment for sex, clinical disease
Figure 2 EBNA-1, but not EA-D nor VZV, increased in patients with MS
(A) Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA-1) immunoglobulin g (IgG) titers are significantly increased in patients with
MS compared with healthy EBV carriers (HEC). No significant differences in IgG levels between MS and healthy controls (HCs)
were observed for (B) early antigen D (EA-D) and (C) varicella-zoster virus (VZV). (D) IgG levels against EBV are similar in (D)
women and men, (E) relapsing-remitting (RR) MS, secondary progressive (SP) MS, primary progressive (PP) MS, or clinically
isolated syndrome (CIS) patients, and (F) patients treated with immunomodulatory drugs or untreated.
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course, and immunomodulatory treatment did not
affect the results (p . 0.20, data not shown). Age at
sampling was significantly associated with EBNA-1
IgG, adjusting our model did not alter the con-
clusions (data not shown). No associations between
these interacting genes and EA-D or VZV IgG were
found (figure 3B). Similar, though less robust, trends
in HEC were observed (figure 3C). Lastly, the 95%
CIs of these interactions were assessed using a boot-
strapping approach with 10,000 random samples to
nonparametrically fit the model. Only very minor
differences after bootstrapping were observed (approxi-
mate bias between the actual data and the bootstrapped
data set was 0.019 or less), indicating that the OR on
EBNA1 IgG levels are accurate. In conclusion, gene-
gene interaction between VCAM1-PRDX5 and
SOX8-MYB-CARD11-CLEC16A is specifically asso-
ciated with EBNA-1 IgG and not with EA-D and VZV.
Gene-gene interaction associated with EBNA-1 IgG is not
secondary to MS.Next, we assessed whether the differ-
ent gene-gene interactions are related to the MS risk
SNPs or secondary to MS disease activity. Therefore,
we used logistic regression with abundant EBNA-1
IgG as the dependent variable and patients with MS
as a covariate. Correcting for MS as a covariate did
not alter the previously described interactions, indi-
cating that the gene-gene interactions itself are
important for the increased EBNA-1 IgG and that the
associations are not secondary to MS alone. In addi-
tion, correcting for HLA-DR did not affect our
results (table e-2).
DISCUSSION Increased EBV seroprevalence and,
more specifically, enhanced IgG specific for EBNA-1
immune response in patients with MS have been
widely reported2,8,10,11 and confirmed in this study.
Longitudinal studies demonstrating EBV infection in
the years preceding the onset of MS2,8,10,11 are often
used as (circumstantial) evidence for a causal role
of EBV in MS. Alternatively, this might be an
epiphenomena as a result of a dysregulated immune
system observed in patients with MS, leading to an
altered handling of the virus. In addition, the virus
might be more active in patients with MS, although
the antibody titers against EA-D, a marker for active
viral replication, are not increased in patients with
MS in the majority of published studies7 as well as in
our study. Lastly, it might be explained that patients
with MS develop IM at a later age than HCs, espe-
cially because EBV infection at later age is more likely
to cause IM.16 The enhanced EBNA-1 IgG titers in
MS might at least partially be explained by both
HLA and non-HLA MS-associated risk genes.13,14
Recently, a study with 1,367 Mexican Americans
assessed association between genome wide over
900,000 SNPs and EBNA-1 seropositivity, irre-
spective of antibody titers. They found that only
HLA-DRB1 and HLA-DQB1 were associated with
EBNA-1 positivity. This is slightly in contrast to the
current study, which might be explained by the fact
that we took the EBNA-1 IgG titers into account in
our models. In addition, their study might have suf-
fered from a power problem with multiple testing
issues, whereas we only assessed MS-associated SNPs.
Lastly, differences in study population (patients with
cardiovascular disease and diabetes mellitus) might
explain the different results.13
MS-associated risk SNPs are shown to affect the
Th- and B-cell transcriptomes.17,18 This may, on the
one hand, influence humoral immune responses
against EBV and on the other hand influence regula-
tion of EBV latency in B cells. To assess whether MS
Figure 3 VCAM1-PRDX5 and SOX8-MYB-CARD11-CLEC16A interactions are
associated with EBNA-1 and EA-D IgG levels
Epstein-Barr nuclear antigen 1 (EBNA-1) (circle), early antigen D (EA-D) (filled square), and
varicella-zoster virus (VZV) (open diamond) immunoglobulin g (IgG) levels were dichotomized,
and logistic regression was performed to assess which MS risk SNPs are associated with
EBNA-1, EA-D, and VZV IgG levels. (A) Univariate logistic regression in patients with MS
showed significance for EBNA-1 IgG above the 75th percentile for VCAM1 (odds ratio [OR]
0.54, 95% confidence interval [CI] 0.36–0.81; p 5 0.003) and PRDX5 (OR 0.63, 95% CI
0.42–0.95; p 5 0.028). Multivariate logistic regression with interaction terms between MS
risk SNPs showed significant interactions of VCAM1*PRDX5 (OR 0.54, 95% CI 0.32–0.89;
p5 0.01) and SOX8*MYB*CARD11*CLEC16A (OR 2.1, 95% CI 1.23–3.66; p5 0.004) for
EBNA-1 IgG, but not HLA-DRB1*1501 (p 5 0.1), in patients with MS (B) and in healthy
Epstein-Barr virus carriers (C). HLA 5 human leukocyte antigen. *p , 0.05, **p , 0.005.
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risk genes are associated with EBNA-1 IgG, we strat-
ified quantitative EBNA-1, EA-D, and VZV IgG
titers as above the 75th percentile to MS-associated
SNPs in healthy EBV carriers and EBV-positive MS
patients and determined the OR of these
polymorphisms.
In this study, we observed a similar trend between
EBNA-1 IgG and of HLA-DRB1*1501 in line with
previously reported associations.12 Moreover, here,
HLA-DRB1*1501 was also associated with EA-D
IgG levels, but not VZV IgG. The HLA-DRB1*1501
influences the repertoire of T cells recognizing peptide
antigens.19 It can therefore be suggested that this
HLA-DRB1*1501 association with EBNA-1 and
EA-D IgG levels reflects Th-/B-cell interactions, hav-
ing an effect on the EBV-specific humoral immune
response of patients with MS.
By contrast, we found that the HLA-independent
MS risk SNPs in VCAM-1 and PRDX5 inversely cor-
related with EBNA-1 IgG levels. Of interest, in
a multivariate logistic regression model, interactions
between VCAM1-PRDX5 and SOX8-MYB-
CARD11-CLEC16A were associated with EBNA-1
IgG levels in a contrasting manner. Strikingly, the
HLA-DRB1*1501 effect on EBNA-1 IgG titer is
overshadowed by these 2 genetic interactions associ-
ated with altered EBNA-1 humoral responses. The
increased EBNA-1 IgG observed in patients with
MS is partially explained by these genetic
interactions.
A similar genetic association was found in HCs
previously exposed to EBV, although not statistically
significant presumably due to the lack of statistical
power. The in part common genetic background of
HCs and patients with MS (e.g., the quite high pro-
portion of HCs carrying MS risk SNPs) might
explain the common effects observed in the immune
response against EBV observed in this study. The
identified MS risk genes associated with EBNA-1
IgG are likely candidates to be functionally involved
Figure 4 Model proposing interaction between EBV latency proteins with here described MS risk genes
(A) Epstein-Barr virus (EBV) infection of B cells induces very late antigen 4 (VLA-4) expression, the ligand of VCAM-1 expressed by activated brain epithelial
cells. (B) Latency-associated membrane protein 1 (LMP1) of EBV induces expression of the peroxiredoxin family of antioxidant enzymes (PRDX5), thereby
reducing reactive oxygen species (ROS) and preventing caspase-mediated apoptosis. EBV-expressed micro RNA (miR)-BART20-5p targets B-cell chronic
lymphocytic leukemia/BAD transcripts, reduces BAD protein levels, and inhibits apoptosis. (C) Analogous to B-cell receptor signaling, EBV LMP2A activates
miR-155 and NF-kB expression via CARD11 and thereby inhibits apoptosis and promotes proliferation. (D) Immediate early lytic EBV protein BZLF1 blocks
loading of peptides to HLA class II in late endosomes by inhibiting CIITA and induced expression of early antigen D (EA-D) and viral capsid antigen (VCA). (E)
CLEC16A is involved in HLA-II antigen presentation via regulation of the endosomal compartment and is important for the production of Ig. Plus and minus
indicate increased and reduced expressions, respectively. BBB 5 blood brain barrier; BCR 5 B-cell receptor; EBNA-1 5 Epstein-Barr nuclear antigen 1;
HLA 5 human leukocyte antigen; IgG 5 immunoglobulin g; NF-kB 5 nuclear factor kappa B.
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in the enhanced humoral immune response, as dis-
cussed here below.
EBNA-1 is expressed in all phases of the EBV
lifecycle except latency 0, where only noncoding
EBV transcripts are expressed.20 EA-D, an EBV
polymerase processivity protein encoded by BamHI
fragment M rightward open reading frame 1, is
restricted to lytic-phase EBV.20 The observed asso-
ciation with EBNA-1 IgG levels therefore suggests
that the genes associated with MS risk SNPs found
in this study interact with latency-associated tran-
scripts of EBV in infected B cells. Strikingly, most
genes associated with the SNPs that correlate with
EBNA-1 IgG levels identified in this study have
been shown to interact with EBV-associated pro-
teins and transcripts.
VCAM1 is expressed by cytokine-activated blood-
brain barrier endothelial cells in MS lesions.21 Mem-
ory B cells constitutionally express the ligand of
VCAM1, integrin a4b1 (very late antigen 4,
VLA-4).17 EBV infection considerably increases
VLA-4 expression in B cells,22 suggesting increased
migration of EBV B cells to the CNS (figure 4A).
PRDX5 is a member of the peroxiredoxin family
of antioxidant enzymes. PRDX5 expression prevents
reactive oxygen species–mediated damage in
mitochondria, thereby inhibiting caspase-induced
apoptosis. The EBV latent membrane protein 2A
induces PRDX5 expression in B cells.23 Alterna-
tively, the PRDX5-associated SNP, rs694739, is
related to B-cell chronic lymphocytic leukemia/
BAD in a type I diabetes study.24 Expression of
BAD is induced during caspase-mediated apoptosis.
The constitutionally EBV-expressed micro RNA
(miR)-BART20-5p targets the 39-untranslated
region of BAD, resulting in decreased BAD levels
and reducing apoptosis in infected B cells.25 EBV
inhibits caspase-mediated apoptosis via PRDX5
and BAD during latent- and lytic-phase infections
(figure 4B), resulting in reduced immune exposure
of EBNA-1, which may partly explain the PRDX5
association with lowered EBNA-1 IgG levels in
patients with MS (figure 4B).
The rs11154801 SNP is linked to Abelson helper
integration site 1 or MYB.26 MYB is a transcription
factor required for B-cell development, and expres-
sion is reduced during the process. Aberrant expres-
sion of MYB leads to lymphoproliferative disorders by
inducing nuclear factor kappa B (NF-kB) and
miR-155 expression.27 Direct interaction of EBV
transcripts or proteins with MYB are not shown.
However, latency-associated membrane protein 1 in-
duces miR-155 and LMP2A/B potently induces
NF-kB expression during latencies I and II, preventing
apoptosis and promoting proliferation.27–29 CARD11 is
a scaffolding protein required for NF-kB activation.
Of interest, gain-of-function mutations in CARD11
lead to B-cell malignancies and anergic T cells by con-
tinuous NF-kB activation, which is severely exacerbated
by EBV infection30 (figure 4C).
The rs7200786 SNP is in close proximity to
CLEC16A, DEXI, and CIITA and alters expression
of DEXI.31 CIITA and CLEC16A are involved in
the regulation of HLA class II via the endosomal
system.32 In addition, CLEC16A knockout in mice
leads to reduced numbers of B cells and an altered
immunoglobulin spectrum.33 The immediate early lytic
cycle–associated EBV transcription factor BZLF1
downregulates MHC class II antigen presentation
through inhibition of CIITA during EBV reactivation
(figure 4, D and E).
rs2744148 is located 36.6 kb downstream of the
nearest gene SOX8, sex-determining region Y-box
8. To date, no interactions of rs2744148 with
SOX8 or EBV transcripts are known.
As we here followed a candidate gene approach
using a set of predefined recently discovered MS risk
genes, we did not correct for multiple testing. This
can be seen as a limitation of this study, with a risk
of being underpowered. To attenuate this issue, we
used first and second cohorts to validate the find-
ings. Moreover, higher numbers obtained by pooled
analysis of patients and controls provided results in
the same direction with lower p values. The results
are plausible, as the SNPs associated with elevated
EBNA-1 IgG are all, except SOX8, highly expressed
in B lymphocytes (data not shown, based on biogps.
org) and already shown to be involved in EBV
latency machinery. In the current study, we were
able to assess 78 of the 100 MS risk SNPs currently
published, thereby possibly missing some genetic
associations with EBNA-1 IgG. It is unlikely that
this has affected the underlying results. It might be
an underestimation of the real genetic contribution
to EBNA-1 IgG levels in MS, as there are even more
MS risk genes to be identified. Lastly, although we
assessed whether or not our results are secondary to
MS disease itself, and we found that correcting for
MS in our regression models did not alter the results,
we cannot fully rule out that MS disease itself is at
least partially associated with increased EBNA-1
IgG. To fully assess this, we would need a larger
cohort of HCs to draw reliable conclusions for this
association.
Taken together, the genes associated with the
identified genomic MS risk SNPs have previously
been shown to be involved in migration (VCAM1),
anti-apoptosis (PRDX5/BAD, MYB/NHI1, and
CARD11), and MHC class II antigen presentation
(HLA-DRB1*1501 and CLEC16A/CIITA) in
latently EBV-infected B cells presumably resulting
in altered EBNA-1 IgG levels. Functional differences
Neurology: Neuroimmunology & Neuroinflammation 7
in these pathways may lead to distinct viral inhibition
and appear at the same time in MS-related autoim-
munity. This deserves to be further explored at a func-
tional level.
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